Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Cancer"
DOI: 10.1016/j.ejca.2017.07.003
Abstract: Background There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review… read more here.
Keywords: plus adt; aap plus; meta; cancer ... See more keywords
Abstract CT190: Latin American patient subgroup analysis of the phase 3 TITAN study: Apalutamide plus ADT in metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2021-ct190
Abstract: Background: Apalutamide (APA) is an approved treatment in various countries of Latin America to treat patients with metastatic hormone-sensitive prostate cancer (mCSPC) patients based on the TITAN study interim analysis, which demonstrated an improved overall… read more here.
Keywords: titan study; cancer; plus adt; apa ... See more keywords
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.22.00193
Abstract: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet… read more here.
Keywords: end; placebo plus; plus adt; enzalutamide plus ... See more keywords